ストックスクリーナーアプリを入手
1.04
5.05%
0.05
アフターアワーズ：
1.04
前日終値:
$0.99
開ける：
$1
24時間の取引高:
33,508
Relative Volume:
0.23
時価総額：
$29.99M
収益：
$40.58M
当期純損益:
$-80.65M
株価収益率:
-0.3122
EPS:
-3.331
ネットキャッシュフロー:
$-8.11M
1週間 パフォーマンス:
-14.75%
1か月 パフォーマンス:
-14.75%
6か月 パフォーマンス:
-48.00%
1年 パフォーマンス:
-33.50%
1日の値動き範囲:
$1.00
$1.04
1週間の範囲:
$0.9633
$1.25
52週間の値動き範囲:
$0.9633
$4.35
Celularity Inc Stock (CELU) Company Profile
Compare CELU vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CELU
Celularity Inc
|
1.04 | 28.55M | 40.58M | -80.65M | -8.11M | -3.331 |
VRTX
Vertex Pharmaceuticals Inc
|
430.14 | 108.36B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
731.77 | 78.05B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
775.03 | 48.74B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
302.11 | 41.16B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
298.16 | 33.17B | 5.36B | 287.73M | 924.18M | 2.5229 |
Celularity Inc Stock (CELU) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-01-30 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2022-12-22 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2022-06-22 | 開始されました | H.C. Wainwright | Buy |
| 2022-04-06 | ダウングレード | Truist | Buy → Hold |
| 2022-01-28 | 開始されました | Oppenheimer | Outperform |
| 2021-11-24 | 開始されました | Morgan Stanley | Equal-Weight |
すべてを表示
Celularity Inc (CELU) 最新ニュース
NEXGEL Closes Celularity Asset Deal, Launches BioNX Surgical - MyChesCo
NEXGEL Appoints Ian Blackman as Chief Financial Officer - Investing News Network
NEXGEL taps M&A veteran as CFO to steer Celularity integration - Stock Titan
NEXGEL expects pro forma annual revenue of roughly $35M following Celularity wound segment acquisition - MSN
Inside the deal: After investor bails, Nexgel scrambles to save acquisition that will triple revenue - The Business Journals
Celularity receives Nasdaq notification - MSN
Celularity Inc (CELU) insider Form 3 details warrants and convertible notes - Stock Titan
Celularity Inc (CELU) insider lists warrant and note holdings - Stock Titan
Barach Family Trust (CELU) reports warrants and convertible notes in Celularity Form 3 - Stock Titan
CELU Celularity tops Q3 2025 EPS estimates and posts sharp revenue growth, as shares dip 2.08%.Guidance Upgrade - Cổng thông tin điện tử tỉnh Lào Cai
Celularity (CELU) What Lies Ahead | Celularity Inc posts 42.5% EPS beat, narrower lossDistressed Pick - Cổng thông tin điện tử tỉnh Lào Cai
Celularity (CELUW) Stock: Is It Breaking Uptrend Earnings ReportNCAV - Xã Thanh Hà
CELU (Celularity Inc.) Q3 2025 EPS beats analyst expectations, registers a small post-earnings stock dip.Community Exit Signals - Cổng thông tin điện tử tỉnh Lào Cai
Family trust reports 20.1% Celularity (CELU) stake from $10M financing - Stock Titan
NEXGEL Reschedules Shareholder Call, Revises Celularity Financing - MyChesCo
NEXGEL closes Celularity biomaterials deal, raises $5.5 million By Investing.com - Investing.com India
Celularity Announces Closing of Transaction with NexGel - Investing News Network
Nexgel Inc co and Celularity enter amendment no. 1 to license agreement on April 17, 2026 - marketscreener.com
Nexgel IncCo to Pay Celularity $13.3 Mln I - Moomoo
NEXGEL (NASDAQ: NXGL) triples revenue outlook with Celularity deal, $6.9M notes - Stock Titan
Celularity Inc. announced that it has received $13.3 million in funding from NEXGEL, Inc. - marketscreener.com
NexGel closes acquisition of products from Celularity - TipRanks
Celularity Closes $13.3 Million Asset Sale to NexGel, Strengthening Focus on Longevity Therapeutics and Balance Sheet 1 - Minichart
NEXGEL New Strategic Partner, Sequence LifeScience, Leads Financing with $5.5 Million to Complete Acquisition of Celularity Degenerative Disease Segment - Investing News Network
Nexgel new strategic partner, Sequence LifeScience, leads financing with $5.5 million to complete acquisition of Celularity degenerative disease segment - marketscreener.com
Celularity Closes NexGel Asset Sale, Refocuses on Cell Therapy - TipRanks
NEXGEL closes Celularity biomaterials deal, raises $5.5 million - Investing.com
Biomaterials company Nexgel announces a key partnership with new strategic partner Sequence Lifescience™ - Bitget
NEXGEL New Strategic Partner, Sequence LifeScience™, Leads Financing with $5.5 Million to Complete Acquisition of Celularity Degenerative Disease Segment - The Manila Times
Celularity Inc. Announces Management Resignations - marketscreener.com
Celularity (NASDAQ: CELU) closes NexGel asset sale as Helena note default looms - Stock Titan
A $5.5M financing gives NEXGEL 6 regenerative products and a new unit - Stock Titan
Celularity Closes Transaction with NexGel to Monetize Biomaterials - Intellectia AI
NEXGEL, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
NEXGEL, Inc. completed the acquisition of Portfolio of Commercial-stage Regenerative Biomaterial Products of Celularity Inc. for 15.8 million. - marketscreener.com
Celularity Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing - The Manila Times
Celularity receives Nasdaq notice for delayed annual report filing By Investing.com - Investing.com Australia
Celularity receives Nasdaq notice for delayed annual report filing - Investing.com
CELULARITY ANNOUNCES RECEIPT OF NASDAQ NOTICE REGARDING LATE FORM 10-K FILING - Moomoo
Celularity announces receipt of Nasdaq notice regarding late form 10-K filing - marketscreener.com
Celularity Inc. Notifies Nasdaq of Non-Compliance with Listing Rules Due to Delay in Annual Report Filing - Quiver Quantitative
NEXGEL Moves Forward Shareholder Update Call to Discuss Celularity Transaction on April 21st at 4:30 P.M. ET - The Manila Times
RSU vesting lifts Celularity (CELU) insider holdings after tax withholding - Stock Titan
Celularity (NASDAQ: CELU) EVP RSUs vest into shares with tax withholding - Stock Titan
Celularity (NASDAQ: CELU) CEO gains shares from RSU vesting - Stock Titan
NEXGEL Reschedules Shareholder Update Conference Call to April 23rd at 4:30 P.M. ET to Provide Update on Celularity Transaction - The Manila Times
NEXGEL Reschedules Shareholder Update Conference Call to - GlobeNewswire
Aug Gainers: What is Celularity Inc Equity Warrants market position2026 Price Momentum & Daily Oversold Bounce Ideas - baoquankhu1.vn
Trend Recap: Is Celularity Inc stock risky to hold now2026 Summary & Verified Technical Trade Signals - baoquankhu1.vn
Risk Recap: Is Celularity Inc Equity Warrant a strong candidate for buy and hold2026 Stock Rankings & Momentum Based Trading Signals - baoquankhu1.vn
NEXGEL signs agreement to acquire regenerative biomaterial portfolio - MSN
Celularity Inc (CELU) 財務データ
収益
当期純利益
現金流量
EPS
0.29%
0.00%
大文字化:
|
ボリューム (24 時間):